Press release
Liver Cirrhosis Market Trends, Epidemiology and Future Outlook
Liver Cirrhosis
The global burden of cirrhosis is rising due to the increasing prevalence of alcoholic liver disease, chronic hepatitis B and C, and non-alcoholic fatty liver disease (NAFLD/NASH). Cirrhosis accounts for significant morbidity and mortality worldwide, making it a major public health concern.
The liver cirrhosis market is evolving with advancements in antiviral drugs, corticosteroids, immunosuppressants, targeted therapies, and liver transplantation, supported by improvements in diagnostic technologies, patient monitoring, and government initiatives. With rising awareness and treatment adoption, the market is expected to grow steadily between 2025 and 2034.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71121
In a Nutshell
• Market Size (2024): USD 7.2 billion
• Forecast (2034): USD 12.5 billion
• CAGR (2025-2034): 5.7%
• Key Growth Driver: Rising prevalence of NAFLD/NASH, hepatitis, and alcohol-related cirrhosis, alongside growing adoption of transplantation and targeted therapies
• Top Region: North America leads due to advanced liver disease management, strong adoption of antivirals, and transplantation infrastructure
• Top Application: Hospitals dominate as primary centers for cirrhosis treatment and transplantation
• Leading Players: Gilead Sciences, AbbVie, Novartis, Pfizer, Takeda, Bristol Myers Squibb, Johnson & Johnson, Roche, Sanofi, Dr. Reddy's Laboratories
• Major Trends: Expansion of NAFLD/NASH-focused therapies, AI-driven diagnostics, regenerative medicine, and liver transplant innovations
• Recent Developments (2025): Companies expanded cirrhosis drug pipelines, launched biosimilars, and initiated clinical collaborations in hepatology
Market Overview
The global liver cirrhosis market is set for consistent growth, driven by:
• Rising incidence of alcohol-related liver disease, viral hepatitis, and NAFLD/NASH
• Expanding role of antivirals, corticosteroids, immunosuppressants, and supportive drugs
• Increasing demand for liver transplantation, the gold standard for advanced cirrhosis
• Growth of targeted therapy and regenerative medicine approaches
• Supportive government and NGO liver health programs
While drug therapies remain crucial for early-stage cirrhosis, transplantation and advanced regenerative solutions dominate late-stage management.
Key Market Drivers
1. Global Surge in Liver Diseases
Lifestyle changes, obesity, alcohol use, and viral hepatitis drive rising cirrhosis cases.
2. Adoption of Antiviral & Targeted Therapies
New drugs are improving survival rates and delaying disease progression.
3. Government & NGO Initiatives
Awareness campaigns and funding for hepatitis elimination accelerate treatment demand.
4. Transplantation Advancements
Improved surgical outcomes, living-donor transplants, and regenerative research boost adoption.
Key Restraints and Challenges
• High Treatment Costs: Transplantation and targeted therapies remain expensive.
• Limited Donor Availability: Organ shortages hinder transplantation adoption.
• Asymptomatic Early Stages: Many patients remain undiagnosed until advanced disease.
• Regional Inequalities: Emerging markets lack access to advanced therapies and infrastructure.
Opportunities & Trends
• NAFLD/NASH Pipeline Expansion: Pharma companies are developing targeted drugs for fatty liver disease.
• AI & Digital Tools: AI-driven imaging and monitoring tools improve early detection.
• Stem Cell & Regenerative Medicine: Emerging as promising future treatment options.
• Biosimilars & Cost-Effective Therapies: Increasing access in emerging economies.
Market Segmentation
By Treatment Type
• Antiviral Drugs
• Corticosteroids
• Immunosuppressants
• Chemotherapy & Targeted Therapy
• Liver Transplantation
• Supportive Care
By Disease Type
• Alcoholic Liver Cirrhosis
• Viral Cirrhosis (Hepatitis B & C)
• Biliary Cirrhosis
• Cryptogenic Cirrhosis
• Others
By End-User
• Hospitals
• Specialty Clinics
• Research Institutes
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
Explore Full Report here: https://exactitudeconsultancy.com/reports/71121/liver-cirrhosis-market
Regional Insights
North America
North America dominates the market due to high prevalence of NAFLD/NASH and alcohol-related cirrhosis, advanced treatment infrastructure, and early adoption of liver transplantation. The U.S. leads with strong reimbursement support and ongoing drug development.
Europe
Europe is the second-largest market, led by Germany, France, Italy, and the UK, supported by public health programs and strong adoption of antivirals and targeted drugs.
Asia-Pacific
APAC is expected to record the fastest CAGR, fueled by high prevalence of hepatitis B & C, alcohol misuse, and growing obesity rates. China, India, and Japan represent key growth markets.
Latin America
Moderate growth is expected in Brazil and Mexico, where cirrhosis prevalence is high but healthcare infrastructure is gradually improving.
Middle East & Africa
MEA remains smaller but is expanding through GCC liver health initiatives, transplant programs, and NGO-backed awareness campaigns
Competitive Landscape
The liver cirrhosis market is led by global pharma companies focused on antivirals, targeted therapies, and transplantation support.
Key Players (as per report):
• Gilead Sciences
• AbbVie Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company
• Bristol Myers Squibb
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Sanofi
• Dr. Reddy's Laboratories
These companies are investing in NAFLD/NASH pipelines, transplant innovations, and affordability programs.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71121
Recent Developments (2025)
1. Gilead Sciences (Jan 2025): Expanded its NASH drug development program with Phase III trials.
2. AbbVie (Feb 2025): Launched a biosimilar for hepatitis C cirrhosis patients in Europe.
3. Novartis (Mar 2025): Partnered with AI firms to enhance early cirrhosis detection through imaging tools.
4. Takeda (Apr 2025): Reported Phase II results for an immunotherapy targeting cirrhosis progression.
5. Pfizer (May 2025): Introduced a patient affordability initiative for cirrhosis medications in APAC.
Events and Implications
• NAFLD/NASH Therapies Gain Traction: Pharma R&D in fatty liver disease is expanding market opportunities.
• AI-Enhanced Diagnostics: Digital tools enable earlier detection and improved patient monitoring.
• Biosimilars Boost Affordability: Expanding access in cost-sensitive regions.
• Transplantation Demand Rising: Organ shortages remain a challenge, but innovations improve outcomes.
Conclusion
The Liver Cirrhosis Market is projected to grow significantly between 2025 and 2034, driven by the rising burden of NAFLD/NASH, hepatitis, and alcohol-related cirrhosis, coupled with advancements in antivirals, targeted therapies, and transplantation.
North America and Europe dominate revenues, while Asia-Pacific emerges as the fastest-growing region, supported by high hepatitis prevalence and rising obesity.
With Gilead, AbbVie, Novartis, Takeda, and Pfizer spearheading innovation in drug development, affordability programs, and AI-driven diagnostics, the market is entering a new era of comprehensive cirrhosis management.
This report is also available in the following languages : Japanese (肝硬変市場), Korean (간경변 시장), Chinese (肝硬化市场), French (Marché de la cirrhose du foie), German (Markt für Leberzirrhose), and Italian (Mercato della cirrosi epatica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71121/liver-cirrhosis-market#request-a-sample
Our More Reports:
Nasopharyngeal Cancer Market
https://exactitudeconsultancy.com/reports/71252/nasopharyngeal-cancer-market
Nerve Sheath Neoplasms Market
https://exactitudeconsultancy.com/reports/71253/nerve-sheath-neoplasms-market
Neuroendocrine Carcinoma Market
https://exactitudeconsultancy.com/reports/71254/neuroendocrine-carcinoma-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liver Cirrhosis Market Trends, Epidemiology and Future Outlook here
News-ID: 4158141 • Views: …
More Releases from Exactitude Consultancy
Irritable Bowel Syndrome (IBS) Market Growth, Trends, Consumer Demand and Key Op …
Introduction
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain, bloating, altered bowel habits (constipation, diarrhea, or mixed), and recurrent discomfort. While not life-threatening, IBS significantly reduces quality of life and is often associated with psychological distress and comorbid conditions such as anxiety and depression.
The global IBS patient pool is increasing due to stressful lifestyles, dietary changes, rising prevalence of gastrointestinal disorders, and greater awareness leading…
Gastroparesis Market Set to Witness Significant Growth by 2025-2034
Introduction
Gastroparesis is a chronic gastrointestinal motility disorder characterized by delayed gastric emptying without mechanical obstruction. It leads to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal discomfort, often resulting in malnutrition and reduced quality of life.
The most common cause of gastroparesis is diabetes mellitus, particularly poorly controlled type 1 and type 2 diabetes. Other causes include post-surgical complications, neurological conditions, and idiopathic cases. With the global rise in…
Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Trends, Epid …
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly referred to as Non-Alcoholic Steatohepatitis (NASH), is a progressive form of fatty liver disease characterized by fat accumulation, inflammation, hepatocyte injury, and varying degrees of fibrosis. It is closely linked to obesity, type 2 diabetes, metabolic syndrome, and cardiovascular risk factors.
MASH/NASH is a major global health burden, with prevalence rising due to the global obesity epidemic and sedentary lifestyles. If untreated, it can progress to…
Gastrointestinal Neuroendocrine Tumors (GI-NETs) Market Insights and Future Outl …
Gastrointestinal Neuroendocrine Tumors (GI-NETs) Market Outlook 2024-2034: Advancing Diagnostics and Targeted Therapies to Drive Growth
Introduction
Gastrointestinal Neuroendocrine Tumors (GI-NETs) are rare malignancies that originate from neuroendocrine cells in the gastrointestinal tract, including the stomach, small intestine, colon. These tumors can be functioning (hormone-secreting) or non-functioning, often leading to late diagnoses. Symptoms vary widely and may include abdominal pain, diarrhea, flushing, and in advanced cases, metastasis to the liver.
Historically considered rare and…
More Releases for Mar
Consumer Adoption Of Smartphones And Tablets Fuels The Mobile Augmented Reality …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
Mobile Augmented Reality (MAR) Market Size Growth Forecast: What to Expect by 2025?
In recent years, the market size of mobile augmented reality (MAR) has been expanding dramatically. The market is projected to increase from $27.57 billion in 2024 to $37.19 billion in 2025, with a compound annual growth…
1 New Article from Happy Smoking - MAR 2025
Happy Smoking is your definitive guide to smoking culture, providing expert reviews, comprehensive guides, and a platform for aficionados to connect and share their passion. We offer responsible, accurate information on enjoying cigars, pipes, and hookahs
.
Austin, TX - MAR 2025: Happy Smoking, a leader in smoking guides and expert reviews, is thrilled to announce the publishing of 1 new article on our platform. This month's update includes a diverse range…
Bungalows Del Mar Office by Harbor Associates in Del Mar, California Defies Nati …
Image: https://www.abnewswire.com/upload/2025/01/5bf83fc4238a3b3089be31e9b2ba64df.jpg
Seal Beach, CA - January 17, 2025 - Harbor Associates, LLC ("Harbor"), a value add and opportunistic buyer and owner in the office market, completed the lease up of the Bungalows Del Mar Office (https://www.thebungalowsdelmar.com/) despite the pandemic and work from home trends and now the recession that has slowed traditional office leasing. This Del Mar office space created by Harbor has been so successful that a rare…
Sport Sunglasses Market is Booming Worldwide | Oakley, Tifosi, Costa Del Mar
A Latest intelligence report published by AMA Research with title "Global Sport Sunglasses Market Outlook to 2028. A detailed study accumulated to offer Latest insights about acute features of the Sport Sunglasses market. This report provides a detailed overview of key factors in the Global Sport Sunglasses Market and factors such as driver, restraint, past and current trends, regulatory scenarios and technology development.
Definition:
Sport sunglasses are specialized eyewear designed to…
Mobile Augmented Reality (MAR) Market 2021 | Detailed Report
The Mobile Augmented Reality (MAR) research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information about the…
Casa Del Mar - Bronx's Exquisite Bar and Restaurant
Bronx, New York City, Release: March 19, 2020
Seafood Dining at Its Best
Are you on a seafood diet?
If you are on a seafood diet, then what's better than sitting at Casa Del Mar, get hooked on seafood at a beautiful restaurant located in the heart of the Bronx that features the most exquisite seafood cuisine of all times.
Established on, the restaurant is an ideal seafood destination for all the gastronomes and…
